Fact CheckerSign in

NCT04309981CompletedPhase 2

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

Source: EU CTIS (euclinicaltrials.eu) · Last updated 26 Jul 2024

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
30 (actual)
First submitted
15 Jul 2024
Start date
26 Jul 2024
Lead sponsor
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
NCT number
NCT04309981
EU CT number
2024-515650-24-00
EudraCT number
2019-001472-11

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 30
  • 7 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Clinic de Barcelona
Coordinator of this site? Confirm its status		BarcelonaSpainCompleted
Hospital Universitario 12 de Octubre
Coordinator of this site? Confirm its status		MadridSpainCompleted
University Clinical Hospital Virgen De La Arrixaca
Coordinator of this site? Confirm its status		MurciaSpainCompleted
Clínica Universidad de navarra
Coordinator of this site? Confirm its status		PamplonaSpainCompleted
Hospital Universitario De Salamanca
Coordinator of this site? Confirm its status		SalamancaSpainCompleted
Complexo Hospitalario Universitario De Santiago
Coordinator of this site? Confirm its status		Santiago de CompostelaSpainCompleted
University Hospital Virgen Del Rocio S.L.
Coordinator of this site? Confirm its status		SevillaSpainCompleted

This page is information, not medical advice. Discuss any trial with your doctor.